Publications by authors named "R Ljung"
Objectives: To report the long-term safety and efficacy of BAY 81-8973 in the LEOPOLD Kids extension phase.
Methods: Patients received BAY 81-8973 (25-50 IU/kg) at least twice weekly. The primary endpoint was safety, assessed in all patients who entered the extension phase (n = 82).
Background: We aimed to estimate XBB.1.5 vaccine effectiveness (VE) against COVID-19-related hospitalizations and deaths during BA.
View Article and Find Full Text PDFArticle Synopsis
- The study aimed to investigate the risk of pulmonary embolism (PE) after COVID-19 vaccination in the Swedish population aged 18 to 84 during the vaccination campaign from December 2020 to December 2022.
- Using a cohort study approach, researchers analyzed data from around 6.1 million vaccinated individuals and identified 12,456 cases of PE, finding slight increases in risk specifically after the first doses of two out of three vaccines.
- Overall, the study concluded that no strong associations existed between COVID-19 vaccinations and PE, suggesting that any increased risk might be due to factors like prioritizing vulnerable populations rather than the vaccines themselves.
The paper outlines the role of the Swedish Medical Products Agency (Läkemedelsverket) in managing medicine shortages. The agency receives reports from pharmaceutical companies, investigates causes, and disseminates information to pharmacies, healthcare providers, and the public. While focusing on mitigating shortages, the agency clarifies its non-involvement in manufacturing or sales decisions.
View Article and Find Full Text PDFObjectives: To estimate the effectiveness and waning of the bivalent BA.4-5 or BA.1 mRNA booster vaccine against Covid-19-related hospitalization and death in immunocompromised individuals.
View Article and Find Full Text PDF